The risk of local recurrence and distant metastases is associated with hormone receptor status in women who underwent breast-conserving therapy for breast cancer, according to a study published online April 14 in the Journal of Clinical Oncology.
The risk of local recurrence and distant metastases is associated with hormone receptor status in women who underwent breast-conserving therapy for breast cancer, according to a study published online April 14 in the Journal of Clinical Oncology.
Paul L. Nguyen, MD, from Harvard Medical School in Boston and colleagues examined whether breast cancer subtype (based on hormone receptor status) was associated with outcome in 793 women who received breast-conserving therapy (lumpectomy and radiation). Of these, 90% also received adjuvant systemic therapy but not trastuzumab.
After a median follow-up of 70 months, the researchers found that the overall 5-year incidence of local recurrence was 1.8% but varied from 0.8% to 8.4% based on positivity for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). Compared with tumors that were positive for ER or PR and negative for HER-2 (which had the lowest recurrence), tumors that were positive for only HER-2 or negative for all three receptors had the highest risk of local recurrence (adjusted hazard ratios 9.2 and 7.1, respectively). Tumors that were ER- or PR-positive and HER-2-positive as well as tumors that were negative for all three receptors had the highest risk of distant metastases (adjusted hazard ratios 2.9 and 2.3, respectively).
“Overall, the 5-year local recurrence rate after BCT (breast-conserving therapy) was low, but varied by subtype as approximated using ER, PR, and HER-2 status,” Nguyen and colleagues conclude.
Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. Published on line: 10.1200/JCO.2007.14.4287.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More